IRVINE, CA, May 20, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has entered into a new Research Collaboration Agreement with Dana-Farber Cancer Institute, Inc. to investigate the potential use of a proprietary extract from the Justicia plant to treat a number of blood disorders.
There are a number of products that have been initially identified for development based on current research on the proprietary extract from the Justicia plant. These potential products could include a nutraceutical for blood health, a biomaterial that could serve as a blood substitute, and an ingredient to be used in the production of meat substitutes.
CBIS 8-K filing on the matter:
“On November 15, 2018, Cannabis Science, Inc. (the “Company”) entered into a Research Collaboration Agreement (the “RCA”) with Dana-Farber Cancer Institute, Inc. The effective date of the RCA is October 19, 2018, and the agreement term is for twelve (12) months. In consideration for this RCA and for performance of the agreed-upon research, the Company will pay Dana-Farber $200,000.
“The purpose of this new RCA between the Company and Dana-Farber is to investigate a proprietary extract from the Justicia plant to potentially treat a number of blood disorders, and for other potential uses. Justicia is the largest genus of flowering plants in the family Acanthaceae. Some Justicia species are cultivated for their ornamental value, while extracts of some species of Justicia are disclosed as being used for treating various indications.
Full press release viewable here: https://finance.yahoo.com/news/cannabis-science-dana-farber-cancer-152804293.html